

(43) International Publication Date
16 June 2011 (16.06.2011)(10) International Publication Number
WO 2011/069951 A1

(51) International Patent Classification:

C07D 233/76 (2006.01) A61K 31/4166 (2006.01)
C07D 401/04 (2006.01) A61P 25/18 (2006.01)
C07D 403/04 (2006.01)

(21) International Application Number:

PCT/EP2010/068946

(22) International Filing Date:

6 December 2010 (06.12.2010)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

0921760.5 11 December 2009 (11.12.2009) GB
1012924.5 30 July 2010 (30.07.2010) GB

(71) Applicant (for all designated States except US): **GLAXO GROUP LIMITED** [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **ALVARO, Giuseppe** [IT/IT]; Via Alessandro Fleming, 2, I-37135 Verona (IT). **DECOR, Anne** [FR/IT]; Via Alessandro Fleming, 2, I-37135 Verona (IT). **FONTANA, Stefano** [IT/IT]; Via Alessandro Fleming, 2, I-37135 Verona (IT). **HAMPRECHT, Dieter** [DE/IT]; Via Alessandro Fleming, 2, I-37135 Verona (IT). **LARGE, Charles** [GB/IT];

Via Alessandro Fleming, 2, I-37135 Verona (IT). **MARASCO, Agostino** [IT/IT]; Via Alessandro Fleming, 2, I-37135 Verona (IT).


(74) Agents: **LAWRENCE, Geoffrey, Mark, Prouse** et al.; GlaxoSmithKline, Global Patents CN9 25.1, 980 Great West Road, Brentford Middlesex TW8 9GS (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: IMIDAZOLIDINEDIONE DERIVATIVES



(57) Abstract: The invention provides a compound of formula (Ia), and pharmaceutically acceptable salts thereof. The invention also provides use of the compounds or salts as modulators of Kv3.1 and/or Kv3.2, and in the treatment of diseases or disorders where a modulator of Kv3.1 and/or Kv3.2 is required, such as depression and mood disorders, hearing disorders, schizophrenia, substance abuse disorders, sleep disorders or epilepsy.

**Declarations under Rule 4.17:**

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*